Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TLSA
Strong SellSinkerTiziana Life Sciences Ltd · Healthcare · United Kingdom · $129M · Avg Vol: $923K/d
COMPANY DESCRIPTION
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing novel therapeutics for oncology, inflammatory diseases, and neurodegenerative disorders. The company's competitive moat is based on its innovative pipeline, particularly its orally administered antibody platform designed for improved drug delivery and efficacy. Tiziana operates as a niche biotech player, emphasizing novel mechanisms of action to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.15 | -0.17 | -0.11 | -0.16 | — | -0.16 | -0.12 | -0.13 | — |
| Shares | 100.6M | 101.5M | 111.5M | 120.5M | +19.8% | 127.3M | — | — | — |
| Debt | 0.4M | 0.2M | 0.1M | 0.5M | 7.7% | 0.5M | — | — | — |
| Equity | 19.6M | 5.5M | 3.9M | 52.0K | -86.1% | — | — | — | — |
| Op CF | -19.6M | -15.7M | -1.5M | -12.8M | — | -12.8M | — | — | — |
| Inv CF | -4.0M | -1.3M | -71.0K | 3.0M | — | — | — | — | — |
| Fin CF | -55.0K | 40.0K | 4.5M | 10.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TLSA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TLSA | Tiziana Life Sciences Ltd(you) | $129M | 1 | Strong Sell |
| SCLP.L | Scancell Holdings plc | $141M | 4 | Strong Sell |
| OKYO | OKYO Pharma Limited | $88M | 5 | Strong Sell |
| 4BB.L | 4basebio PLC | $110M | 11 | Strong Sell |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $52M | 0 | Strong Sell |
| COIL.L | Coiled Therapeutics plc | $51M | 4 | Strong Sell |
| BCYC | Bicycle Therapeutics plc | $294M | 10 | Strong Sell |
| IMM.L | ImmuPharma plc | $30M | 1 | Strong Sell |
| MREO | Mereo BioPharma Group plc | $50M | 12 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.8%